Compare AAPG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAPG | EVO |
|---|---|---|
| Founded | 2009 | 1993 |
| Country | China | Germany |
| Employees | 567 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 1.1B |
| IPO Year | 2025 | 2021 |
| Metric | AAPG | EVO |
|---|---|---|
| Price | $30.35 | $2.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $48.50 | $7.00 |
| AVG Volume (30 Days) | 4.4K | ★ 105.3K |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $54,524,554.00 | ★ $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $368.64 | $8.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.50 | $2.84 |
| 52 Week High | $48.45 | $5.10 |
| Indicator | AAPG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 40.74 |
| Support Level | $28.50 | $2.86 |
| Resistance Level | $32.96 | $3.24 |
| Average True Range (ATR) | 0.70 | 0.10 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 40.31 | 28.57 |
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.